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redirection of epithelial immune 
responses by short-chain fatty acids 
through inhibition of histone 
deacetylases
May Young Lin , Marcel R. de Zoete , Jos P. M. van Putten and Karin Strijbis*
Department of Infectious Diseases and Immunology, Utrecht University, Utrecht, Netherlands
Short-chain fatty acids (SCFAs) are products of microbial fermentation that are important 
for intestinal epithelial health. Here, we describe that SCFAs have rapid and reversible 
effects on toll-like receptor (TLR) responses in epithelial cells. Incubation of HEK293 or 
HeLa epithelial cells with the SCFAs butyrate or propionate at physiological concentra-
tions enhanced NF-κB activation induced by TLR5, TLR2/1, TLR4, and TLR9 agonists. 
NF-κB activation in response to tumor necrosis factor α (TNFα) was also increased by 
SCFAs. Comparative transcript analysis of HT-29 colon epithelial cells revealed that 
SCFAs enhanced TLR5-induced transcription of TNFα but dampened or even abolished 
the TLR5-mediated induction of IL-8 and monocyte chemotactic protein 1. SCFAs are 
known inhibitors of histone deacetylases (HDACs). Butyrate or propionate caused a 
rapid increase in histone acetylation in epithelial cells, similar to the small molecule HDAC 
inhibitor trichostatin A (TSA). TSA also mimicked the effects of SCFAs on TLR–NF-κB 
responses. This study shows that bacterial SCFAs rapidly alter the epigenetic state of 
host cells resulting in redirection of the innate immune response and selective repro-
graming of cytokine/chemokine expression.
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inTrODUcTiOn
The intestinal microbiota is essential for fermentation of complex carbohydrates. As a result of this 
process, the microbiota produces a multitude of metabolites that can easily cross the mucus bar-
rier and exert local and systemic regulatory functions. Such metabolites have been shown to play 
a role in the development of inflammatory bowel diseases (IBD) and even impact brain function 
(1). One group of bacterial metabolites with pleiotropic effects on host immune and energy state 
are short-chain fatty acids (SCFAs). SCFAs are the major end products of bacterial degradation 
of soluble fiber in the large intestine, with acetate (C2), propionate (C3), and butyrate (C4) as the 
main SCFAs produced during carbohydrate and amino acid fermentation (2). Butyrate serves as the 
major energy source for colonic epithelial cells, which metabolize 70–90% of total butyrate in the gut 
(3). The major butyrate-producing bacteria are a phylogenetically diverse group of Gram-positive 
Abbreviations: HDAC, histone deacetylase; IBD, inflammatory bowel disease; SCFA, short-chain fatty acids; TLR, toll-like 
receptors; TSA, trichostatin A.
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Firmicutes, in specific Clostridia spp. (4). The physiological 
concentrations of SCFAs in the lumen of the large intestine can 
range from 1 to 25 mM, while plasma concentrations are in the 
micrometer range (5, 6).
Short-chain fatty acids have important health-promoting 
effects, for example, by stimulating intestinal gluconeogenesis via 
gut–brain neuronal circuits resulting in metabolic benefits for 
the host (7). SCFAs also exert local anti-inflammatory effects and 
patients with colitis benefit from increased dietary fiber or SCFA 
intake, or butyrate enemas (8, 9). At the cellular level, SCFAs 
impact proliferation and immune responses in a cell-specific 
manner. For example, butyrate promotes proliferation and sur-
vival of normal epithelial cells, but induces apoptosis through G1 
or G2-M arrest in cancerous cells (10). In colonic epithelial cell 
lines, butyrate incubation reduces neutrophil migration toward 
Caco-2 cells but increases migration toward HT-29 cells (11). 
Because of their pleiotropic and cell-type-dependent effects, the 
mechanisms of action of SCFAs are poorly understood.
Toll-like receptors (TLRs) are abundantly expressed in the gut 
and regionally or spatially arranged according to their specific 
functions (12). TLR5 is highly expressed in the colon (13) where it 
recognizes flagellin of most motile bacteria and induces protective 
innate and adaptive immune responses (14). Other TLRs present 
in the intestine include TLR4 that recognizes Gram-negative 
lipopolysaccharides (LPS), and TLR2 that senses bacterial lipo-
proteins and lipoteichoic acid. Sensing of microbial components 
by TLRs induces activation of the pro-inflammatory transcrip-
tion factor NF-κB, the release of cytokines and chemokines, and 
activation of adaptive immune responses (15, 16).
Because both bacterial metabolites and TLR activation are 
important for intestinal homeostasis, we here assessed the com-
bined effect of SCFAs on the TLR response in intestinal epithe-
lial cells. Most of the previous studies, investigating the effects 
of SCFAs on cellular processes, focus on long-term effects, for 
example, overnight or 24 h after treatment. Since SCFAs have 
profound effects on cell differentiation and proliferation, and 
these effects could mask the direct effects that SCFAs may have 
on epithelial immune responses, we choose a short exposure 
to SCFAs in the majority of our studies. These conditions also 
more accurately mimic the rapidly increased SCFA levels that 
occur in the intestine after eating. Our data show that butyrate 
and propionate rapidly and reversibly redirect the nature of 
TLR-induced innate immune responses. We provide evidence 
that these effects are most likely caused by SCFA-induced 
alterations in histone acetylation through inhibition of histone 
deacetylase enzymes.
MaTerials anD MeThODs
cell culture
HEK293 cells, stably expressing TLR5, were provided by Dr. B. 
van der Burg (Hubrecht Laboratory Utrecht, The Netherlands). 
HeLa 57A cells stably transfected with a NF-κB-luciferase 
reporter system (17) were provided by Dr. R. T. Hay (Institute 
of Biomolecular Sciences, University of St. Andrews, Scotland). 
The HT-29 cell line was purchased from American Type Culture 
Collection (ATCC, Rockville MD, USA). HEK293, HeLa 57A, 
and HT-29 cells were routinely propagated in T25 flasks in 
DMEM supplemented with 5%, 5%, and 10% FCS, respectively. 
All cell lines were cultured at 37oC and 5% CO2.
reagents
Ultrapure LPS and native flagellin from Salmonella enterica 
serovar Enteriditis strain 90-13-706 (S. enteriditis) were isolated 
as described previously (18). The synthetic tripalmitoylated 
lipopeptide Pam3CSK4 (N-Palmitoyl-S-[2,3-bis(palmitoyloxy)-
(2RS)-propyl]-[R]-cysteinyl-[S]-seryl-[S]-lysyl-[S]-lysyl-[S]-
lysyl-[S]-lysine trihydrochloride), and CpG ODN 2006 were 
purchased from Invivogen (Toulouse, France). The sodium 
salts of butyrate [sodium butyrate (Na-Bu)] and propionate 
[sodium propionate (Na-Pro)] and Trichostatin A (TSA) 
were purchased from Sigma-Aldrich (Zwijndrecht, The 
Netherlands). Tumor necrosis factor α (TNFα) was purchased 
from BD Biosciences (Breda, The Netherlands). The expres-
sion plasmids pTracer-TLR1, pTracer-TLR2, pTracer-CD14, 
and pFlag-TLR5 were constructed as previously described (18, 
19). In every transfection, the pTK-LacZ vector was used for 
the normalization of transfection efficiency. The expression 
vectors pUNO-TLR4, pUNO-MD2, and pUNO-TLR9 were 
purchased from Invivogen. All TLRs and their co-receptors 
were of human origin.
cell Transfection and stimulation
HeLa 57A and HEK293 cells were grown in 48-well tissue culture 
plates (Corning, Schiphol-Rijk, The Netherlands) in culture 
medium up to 50–60% confluency. Transient transfection with 
the plasmids carrying the indicated genes was performed with 
FuGENE 6 (Roche Diagnostics, Almere, The Netherlands) or 
FuGENE HD (Promega, Leiden, The Netherlands) according 
to the manufacturer’s instructions. A 3:1 ratio of FuGENE:DNA 
was used. The total amount of plasmid DNA per transfection 
was 250  ng/well. For transfection of HT-29 cells, adherent 
HT-29 cells at a confluence of ~80–90% were trypsinized and 
re-plated in 48-well tissue culture plates. Directly after plating, 
cells were transiently transfected with ExGen 500 (Fermentas 
GmbH, Germany) according to the manufacturer’s instructions. 
A 6:1 ratio of ExGen 500:DNA was used. The total amount of 
DNA used per transfection was 500 ng/well. Forty-eight hours 
post-transfection, the medium was refreshed with new culture 
medium (including FCS). Cells were pre-treated for 30 min with 
10 mM Na-Bu, 10 mM Na-Pro or 2 μM TSA or left untreated. 
After the pre-incubation period, the medium was not refreshed 
prior to stimulation with the TLR agonists or TNFα unless indi-
cated otherwise. Pre-treated or untreated cells were stimulated for 
5 h with the TLR ligands or TNFα.
nF-κB-luciferase assays
The NF-κB-luciferase reporter system that was used to quantify 
the NF-κB activation following TLR stimulation was described 
previously (20). In brief, cells were washed twice with Dulbecco’s 
PBS and 100  μl of Reporter Lysis Buffer (Promega, Leiden, 
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The Netherlands) was added to each well after which the plate 
was stored o/n at −80oC. Luciferase activity was measured by 
mixing 50  μl of Luciferase Assay Reagent (Promega) to 20  μl 
of defrosted cell lysate followed by direct measurement in a 
luminometer (TD-20/20, Turner Designs, Sunnyvale, CA, USA). 
The β-galactosidase enzyme assay (Promega) was performed by 
adding 50 μl of cell lysate to 50 μl of 2× β-galactosidase assay 
buffer as indicated by the manufacturer’s instructions. Luciferase 
values were normalized against the β-galactosidase values to 
obtain relative luciferase units (RLU). Results are expressed as 
percentage of maximal response of TLR-transfected cells with 
its cognate ligand. In experiments that included TNFα, TNFα 
addition was considered the maximum response.
hDac assay
HDAC activity was measured using the HDAC-Glo assay 
(Promega) according to the manufacturer’s instructions. Cells 
were incubated with SCFA or TSA at the indicated concentrations 
for 30 min or 5 h, transferred to an eppendorf tube and lysed in 
assay buffer with 1% Triton X-100. In a separate experiment, SCFA 
and TSA were added to the assay mixture after cell lysis. The assay 
was performed in 96-well format. Protein lysate was added in the 
linear range of the assay together with 50 μl of assay reagent for a 
total reaction volume of 100 μl. The assay was incubated at room 
temperature for 20 min after which luminescence was measured 
using a Fluorostar plate reader (GE Healthcare).
rna isolation and Quantitative rT-Pcr
Total RNA was extracted from HT-29 cells with RNA-Bee (Bio-
Connect BV, Huissen, The Netherlands). Isolated RNA was treated 
with DNase I (Fermentas) to remove remaining DNA. RNA yield 
was quantified using a NanoDrop ND-1000 spectrophotometer 
(Thermo Scientific, Rockford, IL, USA). RNA transcript levels 
were assessed by quantitative real time PCR (qRT-PCR) using 
the Lightcycler 480 System (Roche, Woerden, The Netherlands). 
For quantitative RT-PCR of human IL-8 and β-actin, previously 
described probe and primer pairs were used (18). All primer 
sequences are listed in Table  1. Primers were labeled with the 
reporter dye 6-carboxy-fluorescein (FAM) and the quencher 
tetramethyl-6-carboxyrhodamine (TAMRA). The RT-PCR with 
probes was performed with the One Step RT-PCR Master-Mix 
kit for Probe Assays (Eurogentec) with 50 ng of RNA per reaction 
and 0.8 μM of primers and probes. Real-time cycler conditions 
were as follows: 30 min at 48oC, 10 min at 95oC followed by 40 
cycles of 15 s at 95oC, and 1 min at 60oC. Quantitative RT-PCR 
of TLR5, monocyte chemotactic protein 1 (MCP-1) and TNFα 
was performed using SYBR Green dye. Primer Express software 
version 2.0 (Abi Prism, Applied Biosystems) was used to design 
cytokine primer sets that amplify 50–80 bp fragments. The qRT-
PCR was performed with 500 ng of RNA, 1 μM of primers and 
the Brilliant III Ultra-Fast SYBR Green qRT-PCR kit (Agilent 
Technologies) according to the manufacturer’s instructions. 
Real-time cycler conditions were as follows: 10  min at 50°C, 
3 min at 95°C, and 45 cycles at 95°C for 5 s and 60°C for 10 s. 
Melting curves were produced by increasing the temperature to 
95°C for 5 s, then 1 min at 65°C followed by slowly increasing the 
temperature to 97°C. Transcript levels were corrected to β-actin, 
and fold expression levels of gene of interests were calculated 
by their Ct value. Unstimulated condition: ΔCt control =  Ct 
target gene control  −  Ct β-actin control. Stimulated condi-
tion: ΔCt treated = Ct target gene treated − Ct β-actin treated. 
ΔCt(control) − ΔCt(treated) values = ΔΔCt, the fold change in 
mRNA = 2ΔΔCt (21).
immunoblotting
Cells were stimulated for 30 min or 5 h with butyrate, propion-
ate, or TSA, washed and lysed directly in Laemmli sample 
buffer (62  mM Tris/HCl pH 6.8; 2% SDS; 10% glycerol; 5% 
2-mercaptoethanol; 0.01% bromophenol blue). Cell lysates 
were briefly sonicated, separated on 15% SDS-polyacrylamide 
gels and transferred to Immobilon-P polyvinylidene difluoride 
(PVDF) transfer membranes (0.45 μm, Millipore, Amsterdam, 
The Netherlands). Blots were blocked with PBS/2% milk/0.1% 
Tween20 and immunostained o/n at 4°C with a polyclonal rab-
bit antibody against acetylated-lysines (#9441, Cell Signaling 
Technology, Bioké, Leiden, The Netherlands) at a 1:1,000 dilu-
tion. Other polyclonal antibodies used were directed against 
acetyl-H3K9 (Merck, 07-352), acetyl-H4K5 (Merck, 07-327), 
acetyl-H4K16 (Merck, 07-329), HDAC1 (Abcam, ab109411), 
HDAC2 (Abcam, ab124974) and HDAC3 (Abcam, ab16047). As 
a secondary antibody, HRP-conjugated goat anti-rabbit antibody 
(Santa Cruz Biotechnology, Heidelberg, Germany) was used. As 
a loading control, GAPDH antibody (Sigma-Aldrich) was used at 
1:10,000 dilution. Signal was visualized with the SuperSignal West 
Pico Chemiluminescent system (Thermo Scientific, Rockford, IL, 
USA) in a ChemiDoc MP (Biorad).
statistical analysis
Statistical analysis was performed by using a paired t-test in 
Graph Pad Prism 4 software. The t-test can be applied to our data 
because each value represents a set of individual measurements. 
All graphs depict mean and standard error of the mean (SEM) of 
three independent experiments. A p-value of <0.05 was consid-
ered significant.
TaBle 1 | Quantitative rT-Pcr primers and probes used in this study.
gene Primer/probe sequence 5′–3′a
β-actin Forward ACCGAGCGCGGCTACAG
Reverse CTTAATGTCACGCACGATTTCC
Probe (FAM)-TTCACCACCACGGCCGAGC-(TAMRA)
IL-8 Forward CTGGCCGTGGCTCTCTTG
Reverse CCTTGGCAAAACTGCACCTT
Probe (FAM)-
CAGCCTTCCTGATTTCTGCAGCTCTGTGT-
(TAMRA)
MCP-1 Forward CAAGCAGAAGTGGGTTCAGGAT
Reverse CAAGCAGAAGTGGGTTCAGGAT
TLR5 Forward GCACTTTTATCAATTGGCTTAATCAC
Reverse AACGAGTCAGGGTACACACAATATATG
TNFα Forward GCAGGTCTACTTTGGGATCATTG
Reverse GCGTTTGGGAAGGTTGGA
aFAM, 6-carboxy-fluorescein; TAMRA, tetramethyl-6-carboxyrhodamine.
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resUlTs
scFas Modulate Tlr5-Mediated nF-κB 
activation
We set out to determine the effects of SCFAs in kidney-derived 
HEK293 and cervical HeLa epithelial cells because they allow 
efficient transfection with TLR expression and NF-κB reporter 
constructs. Cells were transfected with the TLR5 gene and an 
NF-κB dependent luciferase reporter construct and incubated 
with 10 mM butyrate or propionate for 30 min followed by stimu-
lation with the TLR5 agonist flagellin for 5 h. NF-κB responses 
were significantly increased in HEK293-TLR5 cells pre-incubated 
with either butyrate or propionate (Figure 1A). In HeLa 57A cells, 
butyrate enhanced TLR5-induced NF-κB activation, while propi-
onate significantly diminished the TLR5 response (Figure 1B). 
Administration of SCFAs alone (without TLR agonist) did not 
influence baseline NF-κB-luciferase values. The physiological 
concentrations of SCFAs in the gut range from 1 to 25 mM (5, 
6). Therefore, we next tested different concentrations of butyrate 
or propionate to determine the dose-dependency of the observed 
SCFA effects. In HEK293 cells, butyrate most strongly enhanced 
the TLR5-mediated NF-κB activation at a concentration of 
10 mM (Figures 1C,D). The enhancing effect of propionate was 
most pronounced between 1 and 10 mM (Figure 1C). Propionate 
dampened the TLR5 response in HeLa 57A cells irrespective of the 
tested SCFA concentration (Figure 1D); only a non-physiological 
SCFAs concentration of 100 mM reduced the flagellin-induced 
NF-κB activity, likely due to cytotoxicity. Incubation with SCFAs 
for 30 min followed by removal of the metabolites prior to stimu-
lation with bacterial flagellin yielded NF-κB activity levels similar 
to those of flagellin alone for butyrate-treated cells (Figures 1E,F). 
For propionate-treated cells, a minor enhancement rather than an 
inhibition of the NF-κB response was observed (Figures 1E,F). 
These results indicate that the SCFAs need to be continuously 
present to elicit the enhanced TLR response.
Kinetics of the scFas Modulatory effects
We next determined the kinetics of the effects of SCFAs on TLR 
activation. Butyrate or propionate was added to HEK293-TLR5 
or HeLa-TLR5 cells at different time points before or after the 
addition of flagellin. In HEK293-TLR5 cells, the strongest 
enhancement of TLR5 signaling was observed when butyrate 
or propionate was added 2  h before stimulation with flagellin 
(Figure  1G). In HeLa-TLR5 cells, addition of butyrate 16  h 
(Figure 1). To assess whether the effect of SCFAs was limited to 
cell-surface exposed TLRs (TLR5, TLR2/1, and TLR4), a similar 
assay was performed with TLR9 that is located and functional 
in an intracellular compartment (22, 23). While both butyrate 
and propionate treatment showed a trend toward enhancing 
the NF-kB response in response to the TLR9 agonist ODN2006 
in HEK293 cells, these differences did not reach statistical sig-
nificance (Figure 2E). Overall, we conclude that incubation with 
SCFAs for the relatively short period of 30 min in general leads to 
enhancement of TLR–NF-κB activation.
scFas enhance nF-κB activation in 
response to TnFα
To investigate whether the effect of SCFAs was restricted to 
TLR responses, we determined their effects on the cytokine 
TNFα-induced NF-κB activation. In the absence of SCFAs, 
TNFα (5  ng/ml) activated NF-κB in both HEK293 and HeLa 
57A cells. Treatment of the cells with SCFAs (10 mM) prior to 
TNFα incubation enhanced NF-κB responses by two- to four-
fold compared to TNFα alone (Figures  2F,G). The addition of 
FigUre 2 | scFas enhance Tlr and TnFα responses in epithelial cells. TLR–NF-κB assays in HEK293 or HeLa 57A expressing indicated TLR constructs 
and a NFκB-luciferase reporter. Cells were incubated with 10 mM Na-Butyrate or Na-Propionate for 30 min followed by stimulation with the respective TLR ligands 
for 5 h. (a,B) TLR2/1-mediated NF-κB activation in HEK293 or HeLa 57A cells in the presence and absence of SCFAs in response to stimulation with TLR2/1 ligand 
Pam3CSK4. (c,D) TLR4-mediated NF-κB activation in HEK293 or HeLa 57A cells in the presence and absence of SCFAs in response to stimulation with TLR4 
ligand LPS. (e) TLR9-mediated NF-κB activation in HEK293 cells in the presence and absence of SCFAs in response to stimulation with TLR9 ligand ODN2006. 
(F,g) TNFα-mediated NF-κB activation in HEK293 or HeLa 57A cells in the presence and absence of SCFAs. Bars depict mean and SEM of three independent 
experiments. p < 0.05 (*), p < 0.01 (**), p < 0.005 (***).
FigUre 1 | scFas enhance Tlr5-nF-κB responses in epithelial cells. (a,B) TLR5-NF-κB assay in HEK293 or HeLa 57A expressing TLR5 and a NF-κB-
luciferase reporter. Cells were incubated with 10 mM sodium butyrate (Na-Bu) or sodium propionate (Na-Pro) for 30 min followed by stimulation with Salmonella 
enteriditis flagellin for 5 h. (c,D) TLR5-NF-κB assay in HEK293 or HeLa 57A cells as described above with SCFA concentrations ranging from 0 to 100 mM. (e,F) 
Reversibility of the immunomodulatory effect of SCFAs. TLR5-NF-κB assay in HEK293 or HeLa 57A cells incubated with 10 mM Na-Bu or Na-Pro for 30 min after 
which SCFAs of selected groups were removed by washing. (g,h) TLR5-NF-κB assay to investigate pre- and post-incubation effects of SCFAs. Na-Bu or Na-Pro 
was added to HEK293 or HeLa 57A cells 16 h–30 min prior or 1–2 h after addition of flagellin. Bars depict mean and SEM of three independent experiments. p < 
0.05 (*), p < 0.01 (**), p < 0.005 (***).
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prior to flagellin stimulation led to the strongest enhancement of 
TLR5-mediated NF-κB activation, while addition of propionate 
completely abolished NF-κB activation in response to flagellin. 
The addition of butyrate or propionate after initiation of TLR5 
signaling only moderately affected NF-κB activation in both cell 
types (Figure 1H).
Tlr2/1, Tlr4, and Tlr9 responses are 
affected by scFas
To investigate whether the effects of SCFAs were specific to TLR5, 
we characterized TLR2/1 and TLR4 responses in the presence of 
butyrate and propionate using HEK293 and HeLa cells, expressing 
the NF-κB-luciferase reporter and different TLRs. Incubation with 
10 mM butyrate for 30 min enhanced Pam3CSK4-mediated acti-
vation of the TLR2/1 complex (Figures 2A,B) and LPS-induced 
activation of TLR4 (Figures 2C,D) in both cell types. Propionate 
enhanced both responses in HEK293 cells (Figures 2A,C), but in 
HeLa cells these effects on the TLR2/1 and TLR4 responses were 
weak to absent (Figures 2B,D). This was surprising, as propion-
ate strongly reduced NF-κB responses after stimulation of TLR5 
(Figure 1). To assess whether the effect of SCFAs was limited to 
cell-surface exposed TLRs (TLR5, TLR2/1, and TLR4), a similar 
assay was performed with TLR9 that is located and functional 
in an intracellular compartment (22, 23). While both butyrate 
and propionate treatment showed a trend toward enhancing 
the NF-kB response in response to the TLR9 agonist ODN2006 
in HEK293 cells, these differences did not reach statistical sig-
nificance (Figure 2E). Overall, we conclude that incubation with 
SCFAs for the relatively short period of 30 min in general leads to 
enhancement of TLR–NF-κB activation.
scFas enhance nF-κB activation in 
response to TnFα
To investigate whether the effect of SCFAs was restricted to 
TLR responses, we determined their effects on the cytokine 
TNFα-induced NF-κB activation. In the absence of SCFAs, 
TNFα (5  ng/ml) activated NF-κB in both HEK293 and HeLa 
57A cells. Treatment of the cells with SCFAs (10 mM) prior to 
TNFα incubation enhanced NF-κB responses by two- to four-
fold compared to TNFα alone (Figures  2F,G). The addition of 
FigUre 2 | scFas enhance Tlr and TnFα responses in epithelial cells. TLR–NF-κB assays in HEK293 or HeLa 57A expressing indicated TLR constructs 
and a NFκB-luciferase reporter. Cells were incubated with 10 mM Na-Butyrate or Na-Propionate for 30 min followed by stimulation with the respective TLR ligands 
for 5 h. (a,B) TLR2/1-mediated NF-κB activation in HEK293 or HeLa 57A cells in the presence and absence of SCFAs in response to stimulation with TLR2/1 ligand 
Pam3CSK4. (c,D) TLR4-mediated NF-κB activation in HEK293 or HeLa 57A cells in the presence and absence of SCFAs in response to stimulation with TLR4 
ligand LPS. (e) TLR9-mediated NF-κB activation in HEK293 cells in the presence and absence of SCFAs in response to stimulation with TLR9 ligand ODN2006. 
(F,g) TNFα-mediated NF-κB activation in HEK293 or HeLa 57A cells in the presence and absence of SCFAs. Bars depict mean and SEM of three independent 
experiments. p < 0.05 (*), p < 0.01 (**), p < 0.005 (***).
FigUre 1 | scFas enhance Tlr5-nF-κB responses in epithelial cells. (a,B) TLR5-NF-κB assay in HEK293 or HeLa 57A expressing TLR5 and a NF-κB-
luciferase reporter. Cells were incubated with 10 mM sodium butyrate (Na-Bu) or sodium propionate (Na-Pro) for 30 min followed by stimulation with Salmonella 
enteriditis flagellin for 5 h. (c,D) TLR5-NF-κB assay in HEK293 or HeLa 57A cells as described above with SCFA concentrations ranging from 0 to 100 mM. (e,F) 
Reversibility of the immunomodulatory effect of SCFAs. TLR5-NF-κB assay in HEK293 or HeLa 57A cells incubated with 10 mM Na-Bu or Na-Pro for 30 min after 
which SCFAs of selected groups were removed by washing. (g,h) TLR5-NF-κB assay to investigate pre- and post-incubation effects of SCFAs. Na-Bu or Na-Pro 
was added to HEK293 or HeLa 57A cells 16 h–30 min prior or 1–2 h after addition of flagellin. Bars depict mean and SEM of three independent experiments. p < 
0.05 (*), p < 0.01 (**), p < 0.005 (***).
FigUre 3 | Modulation of cytokine expression by scFas. Quantitative RT-PCR of colonic epithelial HT-29 cells incubated with 10 mM Na-Butyrate or 
Na-Propionate for 30 min and stimulated with flagellin for 5 h. (a) mRNA levels of the pro-inflammatory cytokine TNFα. (B) mRNA levels of neutrophil chemotactic 
factor (IL-8). (c) mRNA levels of monocyte chemotactic protein 1 (MCP-1). Bars depict mean and SEM of three independent experiments. p < 0.05 (*), p < 0.01 (**), 
p < 0.005 (***).
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propionate to HeLa 57A cells failed to modulate TNFα-induced 
NF-κB levels, consistent with the results for TLR2/1 and TLR4 in 
these cells. Overall, these experiments show that SCFAs modulate 
the responses of multiple TLRs and TNFα, suggesting that the 
metabolites influence a common step in these inflammatory 
signaling cascades.
redirection of cytokine  
responses by scFas
To learn more about the downstream effects of SCFAs on 
intestinal TLR responses, we incubated colon epithelial HT-29 
cells that endogenously express functional TLR5 with butyrate 
or propionate (10 mM, 30 min pre-incubation) and bacterial 
flagellin (200  ng/ml, 5  h incubation). qRT-PCR was used to 
determine changes in transcript levels for TLR5, TNFα, and 
the chemokines interleukin 8 (IL-8) and MCP-1 (also know as 
CCL2). Exposure to flagellin alone induced a strong increase 
in TNFα, IL-8, and MCP-1 transcript levels compared to non-
stimulated cells (Figures  3A–C) and TLR5 gene expression 
itself was not altered by presence of the SCFAs and/or the 
addition of flagellin (data not shown). TNFα transcript levels 
were higher in the presence of butyrate and propionate, but 
SCFA administration dampened flagellin-induced IL-8 tran-
script levels and even completely abolished the upregulation 
of MCP-1 (Figures 3A–C). These results indicate that SCFAs 
can differentially alter TLR-induced inflammatory gene expres-
sion and, thus, can modulate the nature of the innate immune 
response.
scFas regulate the epigenetic state  
of host cells
How do SCFAs exert their effects on epithelial cells? It was 
previously shown that SCFAs can inhibit HDACs that are 
involved in removal of acetyl groups from histones (24–26). 
Interestingly, HDAC1, HDAC2, and HDAC3 were previously 
shown to be negative regulators of TLR-mediated NF-κB acti-
vation (27). We performed an HDAC activity assay to directly 
determine the inhibitory effects of SCFAs on HDACs. HDAC 
activity was measured in a HeLa cell lysate without SCFAs or in 
the presence of butyrate (10 mM), propionate (10 mM), or the 
potent pan-HDAC inhibitor TSA (2 μM). All three compounds 
had pronounced inhibitory effects on HDAC activity; TSA led 
to a very strong reduction to <1% of the original activity, while 
incubation with butyrate resulted in 10 and 30% remaining 
HDAC activity, respectively (Figure 4A). Next, we determined 
histone acetylation levels in HEK293 and HeLa cells pre-
incubated with butyrate, propionate, or TSA. Cell lysates were 
analyzed by immunoblot with an anti-acetyl-lysine antibody. 
In both cell types, incubation with butyrate, propionate, or 
TSA led to a marked increase of histone acetylation levels, 
even after a short incubation of 30 min (Figure 4B). Histone 
acetylation levels were further increased after a 5-h incubation 
with the compounds. Overall, HDAC protein levels remained 
unchanged (HDAC1 and HDAC2) or slightly decreased after 
incubation with TSA (HDAC3) (Figure  4B). Each histone 
has several lysines that can be modified by acetylation. We 
hypothesized that butyrate, propionate, and TSA may exert 
differential effects on individual HDACs, resulting in a differ-
ence in acetylation of specific histone residues. To investigate 
this, we performed immunoblot analysis using antibodies 
specific for acetylation of histone 3 lysine 9 (H3K9), histone 
4 lysine 5 (H4K5), and histone 3 lysine 9 (H4K16). A similar 
increase in acetylation was observed for H3K9, H4K5, and 
H4K16 in response to butyrate, propionate, and TSA (data 
not shown). The acetylation patterns were comparable to 
the result observed with the general acetyl-lysine antibody 
(Figure  4B). Together these results convincingly show that 
SCFAs have rapid and profound effects on host epigenetics by 
inhibition of HDACs.
effect of hDac inhibition on Tlr 
responses
To ascertain that HDAC inhibition can contribute to the observed 
modulation of the TLR response by SCFAs, we compared TLR5 
FigUre 4 | immunomodulatory effects of scFas are mimicked by the histone deacetylase inhibitor Tsa. (a) HDAC activity in HeLa lysates in the 
presence of 10 mM Na-butyrate, Na-propionate or 2 μM TSA. (B) Immunoblots of HEK293 and HeLa 57A incubated with 10 mM Na-Bu, 10 mM Na-Pro or 2 μM 
TSA for 30 min or 5 h analyzed with anti-acetyl-lysine antibody to visualize total histone acetylation and anti-HDAC1, HDAC2, HDAC3, and GAPDH antibodies. 
(c,D). Immunomodulatory effects of SCFAs are mimics by histone deacetylase inhibitor TSA. TLR5-NF-κB assays of HEK293 or HeLa 57A expressing TLR5 and an 
NF-κB-luciferase reporter. Cells were incubated with 10 mM Na-Bu, 10 mM Na-Pro or 2 μM TSA for 30 min followed by stimulation with S. enteriditis flagellin for 5 h. 
(e) TLR4-NF-κB assays of HEK293 or HeLa 57A expressing TLR4 and an NF-κB-luciferase reporter incubated with SCFA and LPS. Bars depict mean and SEM of 
three independent experiments. p < 0.05 (*), p < 0.01 (**), p < 0.005 (***).
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responses in the presence of SCFAs with the effect of TSA. In 
HEK293-TLR5 cells, TSA enhanced the flagellin-induced 
NF-κB activation to a comparable level as butyrate (Figure 4C). 
In HeLa–TLR5 and HeLa–TLR4 cells, TSA induced a very 
strong NF-κB response after stimulation with flagellin or LPS. 
Surprisingly, TSA by itself (in the absence of TLR ligands) was 
capable of inducing a significantly higher level of NF-κB acti-
vation (Figures  4D,E). Overall, these results show that SCFAs 
and the HDAC inhibitor TSA have similar immunomodulatory 
effects on TLR responses.
DiscUssiOn
Short-chain fatty acids are produced in the intestinal lumen during 
the bacterial fermentation of dietary fibers and are a major cel-
lular energy source for intestinal epithelial cells. Here, we provide 
evidence that SCFAs also redirect epithelial immune responses. 
The SCFAs butyrate and propionate enhanced NF-κB reporter 
activation after stimulation with various TLR ligands as well as 
TNFα. The modulatory effect of the SCFAs was accompanied by 
a change in histone acetylation and could be mimicked by the 
known HDAC inhibitor TSA. In colonic epithelial cells, butyrate 
and propionate selectively altered TNFα, IL-8, and MCP-1 gene 
transcription in response to stimulation with TLR ligands. In 
the presence of SCFAs, the pro-inflammatory cytokine TNFα is 
upregulated, but chemotactic chemokines IL-8 and MCP-1 are 
downregulated. Therefore SCFA may contribute to local contain-
ment of the intestinal inflammatory response. We conclude that 
bacterial SCFAs inhibit host HDAC enzymes, resulting in altered 
immune responses (Figure 5A).
The physiological concentrations of SCFAs in the gut lumen 
are 1–25 mM (5, 6). Most of our experiments were performed 
with a 10 mM SCFA concentration, well within the physiological 
concentration. By addition of SCFAs 30 min before TLR stimula-
tion, we mimicked the temporal spike of SCFA levels after a meal. 
The direct, rapid effects on TLR signaling and cytokine production 
that we observe, therefore, differ from the well-studied long-term 
effects of Na-Bu on cell proliferation and differentiation. These 
long-term effects are generally observed after more than 24  h 
exposure to SCFAs. Our results suggest that transient changes in 
SCFA concentrations in the gut can also redirect the nature of the 
innate immune response.
FigUre 5 | The effect of scFas on hDacs and Tlr responses. (a) Model of immunomodulation of host epithelial cells by bacterial SCFAs. SCFAs are 
produced by microbiota from complex carbohydrates. SCFAs can inhibit HDACs in the cytosol or nucleus. Inhibition of HDACs leads to increased acetylation of 
histones and changes in DNA transcription. In addition, HDAC inhibition may directly impact the NF-κB pathway as the p65 subunit is also regulated by acetylation. 
(B) Structures of SCFAs sodium butyrate and sodium propionate. (c) The effect of SCFA on histone acetylation and chromatin structure. Top: DNA and histones in a 
closed chromatin structure with low levels of transcription. Acetylation by histone acetyl transferases (HATs) induces a open chromatin structure and active 
transcription (bottom). Histone deacetylases remove acetyl groups. Inhibition of HDACs by SCFAs leaves chromatin in the open, transcriptionally active state.
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The pleiotropic effects of SCFAs have been under intense 
investigation since the 1970s when several groups reported 
effects of Na-Bu on cell proliferation, differentiation, and gene 
expression. Following these observations, it was established that 
butyrate inhibits HDACs, resulting in increased histone acetyla-
tion (24–26) (Figure 5C). SCFAs such as butyrate and propionate 
are non-competitive pan-HDAC inhibitors (28). The crystal 
structure of an HDAC-like protein with the HDAC inhibitor 
TSA demonstrates that TSA occupies a hydrophobic cleft on the 
surface of the enzyme away from the substrate-binding site (29). 
The binding site of butyrate on an HDAC enzyme is still not iden-
tified, but it is possible that two molecules of butyrate may bind 
the same hydrophobic cleft (30). Considering the potent effects of 
butyrate on HDACs and histone acetylation, it is surprising that 
the expression of as little as 2% of mammalian genes is affected in 
the presence of butyrate (31, 32).
We show that a short incubation with SCFAs is sufficient 
to sensitize NF-κB activation by TLR5, TLR2/1, TLR4, and 
TLR9. In addition, SCFAs also increased NF-κB activation in 
response to incubation with TNFα. Surprisingly, SCFAs even 
induce low-level NF-κB activation in absence of TLR ligands 
(Figures 1H and 2G). Together these data indicate that SCFAs 
most likely modify a common target in the NF-κB pathway 
rather than modulate a particular signaling component. We 
hypothesized that SCFAs exert their effects on NF-kB signaling 
by inhibition of HDACs and altering chromatin structure. We 
tested this hypothesis by comparing the effects of SCFAs and the 
strong HDAC inhibitor TSA on histone acetylation and NF-κB 
activation in response to TLR ligands (Figure  4). Incubation 
with butyrate, propionate, and TSA lead to rapid changes in 
histone acetylation (Figure 4B). These results are in line with the 
reported effects of these compounds in other systems (33, 34). 
November 2015 | Volume 6 | Article 5549
Lin et al. Modulation of innate immune responses by SCFAs
Frontiers in Immunology | www.frontiersin.org
In addition, TSA was very potent at sensitizing TLR responses 
and NF-κB was even activated in the absence of TLR ligand 
(Figures  4C–E). These data convincingly show that HDAC 
inhibition leads to sensitization of NF-κB responses. The rapid 
increase in SCFA-induced histone acetylation (30 min) corrobo-
rates the rapid alterations in TLR responses (Figures 1–3). These 
results together strongly support the notion that the observed 
effects of SCFAs on epithelial immune responses are caused by 
inhibition of HDAC enzymes, resulting in changes in histone 
acetylation.
The structures of Na-Bu (C4) and Na-Pro (C3) are very simi-
lar, but it is well established that HDAC inhibition by butyrate 
is stronger than inhibition by propionate (Figures 5B,C). The 
HDAC assay that we performed also shows that TSA is the 
strongest HDAC inhibitor, followed by butyrate and propion-
ate (Figure  4A). These differences in HDAC inhibition are 
nicely recapitulated in a TLR–NF-κB activation assay, where 
TSA has the strongest sensitizing effect followed by butyrate 
and propionate (Figures 4C–E). The effect of butyrate is con-
sistently stronger than the effect of propionate (for example, 
Figures 1A,D and 2B). Interestingly, we observed that butyrate 
and propionate have completely opposite effects in a time course 
of SCFA–TLR ligand addition in HeLa but not in HEK293 
cells (Figures  1G,H). Incubation with butyrate enhanced 
NF-κB responses, while propionate completely dampened the 
response. SCFA specificity or different levels of HDAC expres-
sion or accessibility may cause these opposite effects. The human 
HDAC family consists of 11 proteins with distinct expression 
patterns, subcellular localization, target proteins, and protein 
sites. Protein expression of HDAC1, HDAC2, and HDAC3 was 
comparable after incubation with butyrate and propionate, while 
expression of HDAC3 was reduced after incubation with TSA 
(Figure 4B). It is conceivable that butyrate, propionate, and TSA 
inhibit the individual HDACs to a different extent, resulting in 
tailored epigenetic regulation.
Our results fit well with a body of work that establishes class 
I histone deacetylase enzymes HDAC1, HDAC2, and HDAC3 as 
negative regulators of TLR pathways [reviewed by Shakespear 
et  al. and Falkenberg and Johnstone (27, 35). For example, 
HDAC1 inhibits pro-inflammatory gene promoters of IL-12p40, 
Cox-2, and Ifn-β (36–38). Activating transcription factor 3 
(ATF3) and metastatic tumor antigen 1 (MTA1) are downstream 
targets of TLR signaling, which are regulated by HDAC1 and 
HDAC2, respectively (39, 40). Regulation of MTA1 by HDAC2 
prevents activation of inflammatory cytokine genes TNFα and 
IL-1β (40). HDAC1, HDAC2, and HDAC3 are well expressed in 
our epithelial cell lines (Figure 3B). It is, therefore, conceivable 
that the immunomodulatory effects of the SCFAs in our study 
are caused by inhibition of these three enzymes. Besides histone 
targets, HDACs also deacetylate other proteins. The p65 subunit 
of NF-κB itself is acetylated and p65 deacetylation by HDAC3 
leads to association with Iκβa, nuclear export, and dampening 
of the NF-κB response (41). It is, therefore, possible that in addi-
tion to histone modification, SCFAs alter acetylation of NF-κB 
subunits themselves. It remains to be established whether the 
effects of SCFAs on epithelial immune responses are caused by 
changes in histone acetylation, direct modification of NF-κB 
subunits, or both.
Little is known about the role of individual HDACs in dea-
cetylation of specific lysines in histones. It was shown that HDAC 
inhibition by Na-Bu leads to an increase in acetylation of lysine 
9 of histone 3 (H3K9) in mouse subventricular cells (42). Mouse 
embryo HDAC1 knockout cells show an increase in acetylation 
of lysine 5 of histone 4 (H4K5) (43). Acetylation of lysine 9 of 
histone 3 (H4K16) is a very specific acetylation event that is 
regulated by class III HDACs, also known as Sirtuins (44). We 
investigated the impact of SCFAs on H3K9, H4K5, and H4K16 
histone acetylation with acetylation-specific antibodies. To our 
surprise, H3K9, H4K5, and H4K16 acetylation patterns were 
comparable to the pattern observed with the general acetyl-lysine 
antibody (Figure 4B, data not shown). These results indicate that 
SCFAs and TSA have a general HDAC inhibitory effect on all 
HDACs involved in deacetylation of H3K9, H4K5, and H4K16 
and differences in acetylation might be too subtle to detect with 
this method.
One of our most striking observations is that a 30-min incu-
bation with butyrate or propionate enhanced the TLR-induced 
TNFα expression but dampened or even abolished IL-8 and 
MCP-1 transcription in colonic HT-29 cells (Figure  3). The 
pro-inflammatory cytokine TNFα is an essential mediator of 
inflammation in the intestine. IL-8, also known as neutrophil 
chemotactic factor, and MCP-1 are important in the recruitment 
of immune cells to the site of activation. Our results, therefore, 
indicate that SCFAs enhance local pro-inflammatory responses, 
but dampen the recruitment of inflammatory cells to the site 
of infection. Modulation of the epithelial cytokine response by 
SCFAs seems to be cell type and condition dependent, as it was 
previously shown that neutrophil migration toward Caco-2 is 
decreased after overnight incubation with SCFAs and increased 
toward HT-29 (11). In addition, butyrate enhances IL-8 secre-
tion by Caco-2 cells in response to IL-1β and LPS (45). SCFAs 
also have anti-inflammatory effects on cytokine secretion by 
endothelial cells, macrophage and neutrophils (46). Because of 
the complex time and cell-type-dependent effects of SCFAs, it 
is not possible to draw a general conclusion about the impact 
of SCFAs on cytokine responses. However, the tuning of the 
local TLR response by SCFAs, resulting in containment of 
inflammatory response, seems in line with the supposed gener-
ally anti-inflammatory role of SCFAs. For example, butyrate 
has been demonstrated to dampen the NF-κB pathway in 
intestinal biopsy samples and to decrease the production of 
pro-inflammatory cytokines by peripheral blood mononuclear 
cells (PBMCs) (47). Based on our results, we pose that bacte-
rial SCFAs sensitize local epithelial TLR responses and prevent 
large-scale inflammation by selective epigenetic modification of 
innate immune genes.
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